Targeted Protein Degradation– tag –
-
Prelude Therapeutics Receives IND Clearance for Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer Phase 1 Study
MarketBeat USA Overview On September 10, 2026, Prelude Therapeutics announced FDA Investigational New Drug (IND) clearance for PRT13722, an oral KAT6A selective degrader. This compound is being developed for HR-positive/HER2-negative bre... -
Gan & Lee’s First-in-Class AR PROTAC GLR2037 Receives NMPA Approval to Initiate Clinical Trials for Advanced Prostate Cancer
flcube.com China Overview Gan & Lee Pharmaceuticals announced that China's National Medical Products Administration (NMPA) has approved its first-in-class androgen receptor (AR) PROTAC, GLR2037, for clinical trials. This novel therap... -
First PROTAC Therapy for Breast Cancer Approved, Opening New Avenues for Precision Medicine in Advanced, Metastatic Disease with Specific Mutations
Nature Medicine Journal (Facebook) International Overview A PROTAC therapy for breast cancer has received medical approval, pioneering a new era of precision medicine for patients with advanced or metastatic breast cancer harboring speci... -
Protein Accumulation Mechanism is Key to PROTAC Efficacy, Unlocking New Strategies for Refractory Cancers
News-Medical UK Overview Researchers have discovered that the mechanism by which cancer-driving proteins accumulate within tumors significantly influences the efficacy of PROTAC drugs. The study demonstrated that PROTACs are more effecti... -
BRD4-Targeting PROTAC Nanoassemblies Dramatically Enhance FLASH Radiotherapy, Achieving Robust Tumor Suppression
PMC USA Overview New research reveals that BRD4-targeting PROTAC nanoassemblies (APF) significantly amplify the anti-tumor efficacy of ultra-high dose rate FLASH radiotherapy (FLASH-RT). By efficiently delivering the BRD4 degrader ARV-77... -
Unlocking TPD’s Promise: Nanomedicine and Programmable Proximity Platforms Revolutionize Degrader Delivery
MDPI Switzerland Overview Nanomedicine and programmable proximity platforms are emerging as pivotal solutions to the delivery challenges inherent in targeted protein degradation (TPD) technologies. Degrader molecules like PROTACs often f... -
Pin Therapeutics Unveils Oral CK1α Molecular Glue Degrader PIN-5018 for Adenoid Cystic Carcinoma at China TPD Forum, Phase 1 Underway Targeting FDA Accelerated Approval
Korea Biomedical Review South Korea Overview Pin Therapeutics presented PIN-5018, an oral CK1α-selective molecular glue degrader for adenoid cystic carcinoma (ACC), derived from its proprietary PinMARS platform, at the China Targeted Pro... -
Clinical Landscape of Targeted Protein Degradation Explored, Molecular Glues Show Faster Progress with Nanomedicine Delivery Strategies
MDPI Unknown Overview A new review analyzes the clinical landscape of targeted protein degradation (TPD), focusing on PROTACs and molecular glue degraders, noting that the smaller molecular size of molecular glues may enable faster clini... -
Molecular Glue Degraders Expand Druggable Proteome in Cancer Research: Simple Structure Boosts CNS Delivery Potential
Facebook USA Overview Molecular glue degraders, small molecules that stabilize interactions between otherwise non-interacting proteins, are expanding the 'druggable' proteome in cancer research through targeted protein degradation. Unlik... -
PROTACs vs. Molecular Glues: Comparing Targeted Protein Degraders for Size and Permeability in Drug Selection
Drug Target Review UK Overview PROTACs and molecular glues represent two distinct strategies for targeted protein degradation, each with unique advantages and challenges. PROTACs are bifunctional molecules that recruit an E3 ligase to a ...
